Please assess the completion status of the following clinical trial:

Trial Title: Immune Responses to H5N1 Vaccine With and Without AS03 Adjuvant

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
* INCLUSION CRITERIA:~  1. Healthy status confirmed by History, Physical Exam and blood work through the CHI Screening Protocol.~ 2. Age 21 years to 45 years~ 3. Able to comprehend the investigational nature of the protocol and provide informed consent~ 4. Must be willing to use effective birth control for one month before, during and for two months after the last vaccination.~EXCLUSION CRITERIA:~1. Severe allergies to eggs or their products, chicken proteins or to any component of the influenza antigen preparation.~2. Recipient of AS03 vaccine at any time in the past~3. Recipient of the seasonal influenza vaccine within the past 3 months.~4. Prior severe reactions to vaccines, including influenza vaccines (e.g. anaphylaxis, angioedema or urticaria)~5. Participation on any blood collection or blood donation procedure during study that will bring the total blood draw \>550ml over 8 weeks~6. Current pregnancy (women of child bearing potential must have a negative serum pregnancy test done on screening within 1 week of protocol accrual)~7. Currently breast-feeding~8. History of Guillain Barre syndrome~9. Acute illness with patient reported temperature of 38 (Infinite)C or greater within 3 days prior to the proposed time of administration.~10. Any history or presence of serious illness, bleeding disorders or autoimmune disorders, or planned surgeries.~11. Weight less than 50 kg (110 pounds)~12. History of hepatitis or liver disease.~13. Subjects receiving immunosuppressive therapy.~14. Presence of HLA DQB1\*06:02, the narcolepsy risk associated allele.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- AS03 adjuvanted (Type: EXPERIMENTAL): Adminsitered day 1, booster at Day 21
- unadjuvanted (Type: EXPERIMENTAL): Administer day 1 and booster at Day 21

Based on this trial design, predict the completion outcome and termination type (if applicable).